Concentration screening, cytotoxicity assay, FDA-PI staining, rhodamine phalloidin-Hoechst 33258 staining, alkaline phosphatase (ALP) activity assay, ALP staining, osteogenic-specific gene expression and Alizarin red staining of monolayer-cultured osteoblasts. A Screening of nerve growth factor (NGF) using various concentrations (0.625, 1.25, 2.5, 5, 7.8125, 10, 15.625, 20, 31.25, 62.5, 125, 250 μg ml −1 ) on 2D cultured osteoblasts using the MTT method after 3 days of treatment (n = 3). B Cytotoxicity assay with NGF at 0, 2.5, 5 and 10 μg ml −1 on days 2, 5 and 8 (n = 9). C (a-d) FDA-PI staining of osteoblasts treated with NGF at 0, 2.5, 5 and 10 μg ml −1 after 8 days of treatment (Scale bar = 200 μm). C (e-h) Rhodamine phalloidin-Hoechst 33258 staining of a monolayer culture treated with 0, 2.5, 5 and 10 μg ml −1 NGF after 8 days (Scale bar = 100 μm). D ALP activity assay of osteoblasts treated with 0, 2.5, 5 and 10 μg ml −1 NGF on days 2, 5 and 8 (n = 9). E (a-d) ALP staining of osteoblasts treated with 0, 2.5, 5 and 10 μg ml −1 NGF after 8 days (Scale bar = 500 μm). F (a-f) Relative expression of bone morphogenetic protein-2 (BMP2, F (a) ), runt-related transcription factor 2 (RUNX2, F (b)), alkaline phosphatase (ALP, F (c)), bone sialoprotein (BSP, F (d)), osteocalcin (OCN, F (e)) and alpha-1 type I collagen (COL1A1, F (f)) in osteoblasts treated with 0, 2.5, 5 and 10 μg ml −1 NGF on days 2, 5 and 8 (n = 3). G (a-d) Alizarin red staining of osteoblasts treated with 0, 2.5, 5 and 10 μg ml −1 NGF after 8 days (Scale bar = 500 μm). The values are presented as the means ± standard deviation. Bars with different letters at the same time point are significantly different from each other at P < 0.05, and bars with the same letter exhibit no significant difference.
